Related by context. All words. (Click for frequent words.) 61 FOR AN OPEN 59 Pharmacokinetic PK 59 Platelet Inhibition 59 Predictive Toxicology 59 By BBH FX 59 EURIDIS 59 Carotid Artery Stenting 58 Patient Outcomes 58 Venous Thromboembolism 58 HYVET 58 Randomized Evaluation 57 Carotid Endarterectomy 57 Clinical Evaluation 57 prospective multicentre 57 RE LY ® 57 MEND CABG 57 Oral Fingolimod 57 STRIDE PD 57 ACCORD Lipid 57 Acute Myocardial Infarction 57 Insulin Therapy 57 Phase III AFFIRM 57 Clinical Outcome 57 Aggressive Reduction 57 Randomized Phase II 57 Risk Stratification 56 Investigational Drug 56 Carotid Stenting 56 Left Ventricular Dysfunction 56 Lipid Lowering Treatment 56 Acute Coronary Syndromes 56 Cost Effectiveness 56 MEDCAC 56 LUMINATE 56 Multicenter Phase 56 Asthma Intervention 56 ENDEAVOR III 56 Intervention Effectiveness 56 Digital Mammographic Imaging 56 Coronary Intervention 56 Hepatocellular Carcinoma 56 BOLDER II 56 Dose Ranging 55 Observational Studies 55 RNAi Therapeutic 55 Demonstrates Sustained 55 ExTRACT TIMI 55 ENDEAVOR IV 55 Echocardiographic 55 Cardiovascular Outcomes 55 Clinical Antipsychotic Trials 55 BARI 2D 55 Randomised 55 Gastric Cancer 55 APPRAISE 55 Pharmacodynamic 55 MERIT ES 55 Pharmacoeconomics 55 Comparative Effectiveness 55 Practice Guideline 55 CLARITY TIMI 55 Pharmacogenomic 55 HORIZONS AMI trial 55 Clinical Practice Guideline 55 Phase 2b Study 55 BCIRG 55 Dose Escalation 55 Antimicrobial Resistance 55 Intervention Effectiveness CATIE 55 NICE SUGAR 55 Prospective Multicenter 55 Randomized Double blind 55 Rosuvastatin 55 Aromatase Inhibitors 55 Randomized controlled 55 Randomized Controlled 54 Bioequivalence 54 Stent Thrombosis 54 Clinical Trial Results 54 Outpatient Setting 54 Ranolazine 54 multicentre randomized 54 Antiplatelet Therapy 54 phase IIIb 54 PCI ExTRACT TIMI 54 Pulmonary Arterial Hypertension 54 CARE HF 54 Quality Indicators 54 Ovarian PLCO Cancer 54 Meta Analysis 54 Dialysis Outcomes 54 Prostate Cancer Outcomes 54 BRIM3 54 Process Validation 54 GISSI 54 See CLINICAL PHARMACOLOGY 54 Tumor Response 54 Critical Success Factors 54 RE LY trial 54 PLCO 54 ACCORD Eye 54 multicenter randomized controlled 54 CURRENT OASIS 7 54 Analytical Method 54 journal Resuscitation 54 Product Commercialization 54 fidaxomicin Phase 54 Lung Cancer Trial 54 Phase III Clinical Trial 54 #.# OBJECTIVE STOP@#.# 54 Novel Therapeutic 54 Pre Exposure Prophylaxis 53 Intervention Trial 53 Low Carbon Economy 53 Prospective Randomized 53 Horizon Scanning 53 Clinical Guideline 53 Adverse Event 53 Nonclinical 53 HCV SPRINT 53 Prognostic Value 53 Observational Study 53 Anticancer Drug 53 Acute Ischemic Stroke 53 LUX Lung 53 Prostate Cancer Prevention 53 Cancer Biomarkers 53 Medication Adherence 53 Pharmacokinetic 53 Laryngeal Cancer 53 Refractory Angina 53 Toxicity Testing 53 PERSEUS 53 Multicenter 53 Renal Cancer 53 Coronary Revascularization 53 Prostate AdenoCarcinoma Treatment 53 Statistical Significance 53 ONTARGET 53 Arterial Hypertension 53 RNAi Therapeutics 53 ARBITER 6 53 Personalised Medicine 53 Clostridium difficile Infection 53 Clinical Practice Guidelines 53 Patient Recruitment 53 RECORD1 53 Light Olefins 53 Neoadjuvant Chemotherapy 53 TAXUS ARRIVE 53 Phase Ib II 53 Improving Outcomes 53 Acute Decompensated Heart Failure 53 Nymox NX 52 Hematological Cancers 52 ST Segment Elevation 52 Hemodialysis Patients 52 Clinical Therapeutics 52 Cardiotoxicity 52 Shows Efficacy 52 ICON7 52 Unfractionated Heparin 52 Osteoarthritis Pain 52 Lung Injury 52 Diabetes Complications 52 Pressure Monitoring 52 Molecular Diagnostic 52 Severe Asthma 52 Currency Majors Technical 52 Glucosamine Chondroitin Arthritis 52 Phase IIIb 52 Meets Primary Endpoint 52 Analytical Tool 52 Preclinical Models 52 Breast Density 52 Phase 1a clinical 52 TRANSFORMS 52 Localized Prostate Cancer 52 FOREXYARD Daily Forex 52 Stable Angina 52 OBPM 52 Subgroup analysis 52 Diabetic Foot Ulcer 52 Val HeFT 52 prospective observational cohort 52 Statistically Significant 52 SUCCEED trial 52 Carotid Revascularization Endarterectomy vs. 52 Study Validates 52 Long Lesion 52 SPARCL 52 Hepatitis C Virus 52 multicenter multinational 52 Anticoagulation 52 Toxicogenomics 52 Prostate Disease 52 Screening Trial 52 Oral Anticoagulants 52 SPIRIT FIRST 52 Cancer Prevention ATBC 52 EuroIntervention 52 IMPACT IMmunotherapy 52 Schizophrenia Treatment 52 Coronary CTA 52 multicenter phase 52 Ischemic Stroke 52 Randomized Study 52 Multicenter Trial 52 Solid Tumors 52 Phase III Trial 52 Pivotal Phase III 52 ANCOVA 52 SABCS 52 Relapsing Multiple Sclerosis 52 Preliminary Findings 52 Pooled Analysis 52 Evaluation Process 52 Acute Heart Failure 52 Adjuvant Breast Cancer 52 Advanced Heart Failure 52 TAXUS ATLAS 52 NSABP B 52 Lung Cancer Screening 52 ANCHOR trial 52 Antibacterial Drug 52 phase IIa 52 Intensive Care Medicine 52 Tuberculosis Vaccine 51 Rotavirus Vaccine 51 Histologic 51 Investigational Drugs 51 First Patient Enrolled 51 Double Blind Randomized 51 Gender Differences 51 AVERROES 51 Clinical Outcomes 51 Medium Term Expenditure 51 Exelixis XL# 51 Feasibility Assessment 51 Interoperability Standards 51 Meta analyzes 51 Watchful Waiting 51 entitled Formulary Advantages 51 Antihypertensive 51 ACCF AHA 51 Metabolic Endocrinology 51 Phase 2b monotherapy 51 Organisational Change 51 Investigator Initiated 51 covariance ANCOVA 51 Randomized Trials 51 Hypercholesterolemia 51 Hsp# Inhibitor 51 Phase 2b Clinical Trial 51 Pralatrexate 51 Placebo Controlled Trial 51 Earned Value 51 subanalysis 51 Randomized Controlled Trials 51 Clinical Effectiveness 51 Pre Feasibility Progress 51 Low Dose 51 formal pharmacokinetic PK 51 biostatistical analysis 51 Coronary Artery Bypass Graft 51 Unstable Angina 51 Protein Therapeutics 51 Treatment Outcome 51 Phase IIIB IV 51 Talmey Drake Research 51 Myocardial Ischemia 51 CHARM Added 51 Ischaemic 51 Contingent Workforce Management 51 Randomized Clinical Trials 51 Clinically Significant 51 IND Filing 51 Clinical Efficacy 51 Successfully Completes Phase 51 Pandemic Influenza Vaccines 51 Active Ulcerative Colitis 51 PROactive Study 51 Practical Applications 51 R# #mg BID 51 Continuous Monitoring 51 Sirolimus Eluting Stent 51 BRIM2 51 Acute Pain 51 Hormone Refractory Prostate Cancer 51 Quantitative Risk 51 secondary efficacy endpoint 51 prospectively defined 51 Dyslipidemia 51 SYNTAX 51 Edge STudy 51 Gout Drug 51 Pre RELAX AHF 51 Myocardial Perfusion 51 Cervical Dysplasia 51 FDG-PET/CT 51 Hematological Malignancies 51 Pharmacoeconomic 51 Cancer Biomarker 51 Postmarketing 51 Hedgehog Pathway Inhibitor 51 Initiates Phase III 51 Stenting Trial CREST 50 MelaFind pivotal 50 Subgroup Analysis 50 Guideline Update 50 Pharmacoepidemiology 50 Cardiometabolic 50 PROTECT AF 50 Combination Treatment 50 Erythropoiesis Stimulating Agents ESAs 50 Capsules CII 50 Diamyd Medical Diamyd 50 Renal Cell Carcinoma 50 Accelerating Clinical Trials 50 Clinical 50 Postmarket 50 observational cohort study 50 Sipuleucel T 50 Prolongs Survival 50 Diastolic Heart Failure 50 Topline Results 50 Therapeutic Antibody 50 Sibutramine Cardiovascular Outcomes 50 Percutaneous Tibial Nerve Stimulation 50 pivotal bioequivalence 50 Intervention Trial GAIT 50 JAK Inhibitor 50 Demonstrate Significant 50 PROactive study 50 Coxe Commodity 50 Protein Expression 50 Controlled Trial 50 Preterm Labor 50 Hepatotoxicity 50 Biostatistical 50 HCV Protease Inhibitor 50 Antiepileptic Drugs 50 HORIZONS AMI 50 RIO Lipids 50 Abciximab 50 Metastatic Renal Cell Carcinoma 50 Cholinesterase Inhibitors 50 Mitigation Strategies 50 Ecological Synthesis 50 Benign Prostatic Hyperplasia 50 Breast Carcinoma 50 Lung Cancer Drug 50 BMC Musculoskeletal Disorders 50 Severe Sepsis 50 Phase Ib IIa 50 Significantly Improved 50 Prostate Lung Colorectal 50 Consensus Statement 50 CLIRS 50 Psychiatric Diagnosis 50 Data Extraction 50 Clinical Significance 50 Microdosing 50 PFO migraine 50 Resource Utilization 50 Better Outcomes 50 Acute Stroke 50 Confirmatory 50 Tiotropium 50 Pimco Floating Rate 50 Innovation Imperative 50 Phase III Psoriasis 50 Vaccine Immunology 50 Myocardial Infarction 50 Nicotine Vaccine 50 Systematic Approach 50 Confirms Efficacy 50 Buffalo Neuroimaging 50 Clinical Decision Making 50 Reproductive Toxicology 50 Rosiglitazone Evaluated 50 Ischemic Events 50 Issues Shareholder 50 randomized multicenter trial 50 Vertebral Fracture 50 confirmatory clinical 50 Nonalcoholic Steatohepatitis 50 Nesiritide 50 Novel Therapies 50 Initiates Clinical 50 Randomized Double Blind 50 Antifungals 50 -0 Content Outline 50 Lupus Drug 50 Functional Capacity 50 Analytical Methods 50 Nord Trøndelag Health 50 Phase IIb Clinical Trial 50 Resubmission 50 Immunogenicity 50 Gastrointestinal Stromal Tumors 50 substudy 50 Phase Ib Clinical Trial 50 ABCSG 50 riociguat 50 Hematological 50 TG MV 50 Chemotherapeutic Agents 50 Molecular Basis 50 retrospective observational study 50 Nutritional Status 50 Demonstrates Efficacy 50 Therapeutic Approaches 50 Postmenopausal Hormone Therapy 50 Patient Enrollment 50 Cardiorespiratory fitness 50 TB Vaccine 50 Minimally Invasive Surgical 50 ECASS 50 DEFINITIVE AR 50 STEP BD 50 Exploratory IND 50 Meta Analyses 50 Ophthalmic Drug 50 User Behavior 50 Menopausal Symptoms 50 Performance Measurement 50 Ocular Hypertension Treatment 50 #:#-#,# CrossRef Medline [002] 50 Telik Announces 49 Patient Oriented 49 florbetaben 49 ORAL Sync 49 Multiple Myeloma Patients 49 Pharmacokinetic parameters 49 Genetically Engineered Animals 49 Clinical Trial Evaluating 49 Vendor Selection 49 Cholesterol Levels SPARCL 49 Hematologic Malignancies 49 #F FDG PET 49 meta regression 49 Inflammatory Arthritis 49 Neurosurgery Spine 49 Biological Effects 49 Molecular Genetic 49 Decompensated Heart Failure 49 Immunomedics Announces 49 Combination REOLYSIN R 49 Arch Neurol 49 Cardiac Markers 49 CAMMS# 49 fidaxomicin Phase 3 49 Randomized trials 49 journal Biomacromolecules 49 Aruvian R'search presents 49 Diagnostic Criteria 49 Comprehensive Wildlife Conservation 49 Potent Inhibitor 49 Cancer Immunotherapy 49 Adverse Outcomes 49 Database Auditing 49 Deploying Hosted 49 Culturally Competent 49 Antitumor Activity 49 Systemic Therapy 49 SWOG 49 Surgical Treatment 49 CALGB 49 RE SURGE 49 Quantitative Impact 49 Therapeutic Effects 49 randomized controlled multicenter 49 Pharmacovigilance 49 Assessment Questionnaire 49 Phase IIIa 49 Randomised Controlled Trial 49 BizAcumen LLC 49 Biopharmaceutical Industry 49 Colorectal Screening 49 Multichannel Campaign 49 Late Breaker 49 Roadmapping 49 MedPredict 49 MiDAS 49 Prospective Randomized Trial 49 Folfox 49 Cardiac Imaging 49 Treating Depression 49 Treating Chronic 49 Cardiogenic Shock 49 Topics Covered Executive 49 evaluating mipomersen 49 Targeted Therapy 49 chemoprevention trials 49 AVADO 49 CT Colonography Trial 49 number NCT# ClinicalTrials.gov 49 Assessment Methodology 49 Immunotherapeutic 49 Nonalcoholic Fatty Liver Disease 49 Angiographic 49 Prostate Cancer Treatment 49 NAMCS 49 multicentre prospective 49 prospective observational studies 49 Healthy Behaviors 49 KRN# 49 Shows Promising 49 undergoing Percutaneous Coronary 49 Efficacy Study 49 Radiation Dose 49 DASISION 49 Cancer Stem Cells 49 Patient Adherence 49 Cancer Incidence Mortality 49 Anticoagulant 49 Ionizing Radiation 49 Biomarker Study 49 Hematologic 49 Kaplan Meier analysis 49 secondary efficacy endpoints 49 Improving Patient Care 49 Managing Complexity 49 Platelet Function 49 Versus Placebo 49 CRLX# 49 Estrogen Receptor 49 Multivariate logistic regression 49 Study Reinforces 49 Opportunity Assessment 49 Trial NLST 49 Postmenopausal Women 49 Lipid Lowering 49 RE MODEL 49 Inflammatory Markers 49 Confirmatory Phase 49 Therapeutic Potential 49 Women Ischemia Syndrome 49 SPIRIT III 49 Drug Repositioning 49 Phase III ALLEGRO 49 Cyber Threat 49 Repeatable Battery 49 Vertebral Compression Fracture 49 Relapsing Remitting Multiple Sclerosis 49 Pregnancy Outcomes 49 Surgical Outcomes 49 Airborne Magnetic 49 Chicago Multidisciplinary Symposium 49 Cancer Therapies 49 Wkly Tech 49 Phase III psoriasis 49 Bipolar Disorders 49 Cochrane Systematic Review 49 Cytogenetic 49 Cosmetic Surgery Procedures 49 Diagnostic Accuracy 49 Glucose Monitoring 49 TASKi2 49 Phase 1a 49 Cardiovascular Diseases 49 Phase IIB 49 PAREXEL Consulting 49 Blood Pressure Lowering 49 Transdermal Delivery 49 Erythropoietic 49 Southwest Border Counternarcotics 49 Motility 49 Preventing Medication Errors 49 RECIST Response Evaluation Criteria 49 Advanced Melanoma 49 Reanalysis 49 Diabetic Patients 49 Long Term Efficacy 49 KRAS status 49 pharmacoeconomic analysis 49 EHR Adoption 49 Initiates Clinical Trial 49 longitudinal cohort study 49 Decision Matrix Selecting 49 Universal Flu Vaccine 49 Functioning GAF 49 Climate Modeling 49 Rheumatoid Arthritis Patients 49 preclinical efficacy 49 VADT 49 Study Analyzes 49 Afatinib 49 Outcome Measures 49 Psychosomatic Research 48 Diabetic Macular Edema 48 CABG Surgery 48 Phase 2a Trial 48 Digital Imaging Complexion 48 Medicure Announces 48 Novel Approach 48 Structural Changes 48 Anti Clotting Drug 48 Companion Diagnostics 48 Randomized phase 48 phase IIb study 48 Protease Inhibitor 48 RMA AFS Risk 48 Hepatitis C Infection 48 Hazardous Drugs 48 REALITY Trial 48 clevidipine 48 comparative genomic 48 Performance Benchmarks 48 Operational Effectiveness 48 Randomized Clinical Trial 48 Airborne Geophysical 48 Renal Cell Cancer 48 Outcome Sciences 48 Workplace Productivity 48 EMBO Molecular Medicine 48 Antiretroviral Therapy 48 Avian Flu Vaccine 48 IMPACT DCM 48 Study Showed 48 prospective longitudinal 48 Endocrine Practice 48 STEALTH C 48 Sustained Efficacy 48 Longitudinal Studies 48 Suicidality 48 Microbicide Development 48 Operational Efficiency 48 #:#-#,# [002] 48 randomized Phase 2b 48 Systematic Review 48 Preclinical Study 48 Pharmacotherapy 48 Study Evaluating 48 Pluripotent Stem Cells 48 Preclinical Clinical 48 Fracture Risk 48 Pervasive BI 48 NCT# ClinicalTrials.gov 48 Clinical Trials 48 BMC Psychiatry 48 Osteoporosis Drug 48 Reveals Significant 48 Demonstrated Significant 48 Bone Metastases 48 Alzheimer Disease Genetics 48 CLL8 48 Differentiator 48 Epilepsia 48 Home Buyer Seller 48 randomized multicenter 48 Workplace Skills 48 Improve Patient Outcomes 48 Mitral Valve Repair 48 Preclinical Data 48 Bosutinib 48 SF #v# 48 XPEL Announces 48 Clinical Trial Data 48 Anti Tumor 48 Pivotal Trial 48 Multicenter Study 48 Quantifiable 48 Sleep Disturbances 48 BioSante Pharmaceuticals Reports 48 Diabetologia 48 PreCISe 48 Differential Diagnosis 48 Non Inferiority 48 Antiepileptic Drug 48 Celecoxib APC trial 48 Radiofrequency Ablation 48 Radiation Induced 48 PLoS Clinical Trials 48 Authorized Generics 48 Epilepsy Surgery 48 univariate 48 #:#-#,# Medline 48 Recurrence Risk 48 Bone Metabolism 48 ARIXTRA R 48 VIVUS Qnexa 48 Mutagenesis 48 Trial PCPT 48 subgroup analyzes 48 Reperfusion 48 Prioritisation 48 Demonstrates Significant 48 Histopathological 48 #:#-#,# [003] 48 Adjuvant Therapy 48 Blood Pressure Monitoring 48 NIH Consensus 48 Sentinel Lymph Node Biopsy 48 Vitro Diagnostic Market 48 Haemostasis 48 multicentre 48 Atopic Dermatitis 48 Intergroup Exemestane Study 48 REVIVE Diabetes 48 PK PD modeling 48 Insulin Sensitivity 48 Acetonide 48 Cervical Spine 48 Depressive Symptoms 48 Pharmacogenetic 48 Cognitive Aging 48 Cardiovascular Risk Reduction 48 Initiated Phase 48 Improve Processes 48 Therapeutic Targets 48 Phase IIb Trial 48 Hospital Acquired Pneumonia 48 Phase IIb III 48 IFRS changeover 48 Metabolomics 48 Evaluation WISE 48 TRA 2P 48 Investigational Compound 48 pharmacodynamic parameters 48 Test Methodology 48 Pivotal Study 48 ORAL Solo 48 Pulmonary Drug 48 iPrEx 48 Cardiac Rhythm 48 DEFER 48 Presents Positive 48 NCCN Oncology 48 downhole gamma logging 48 ADHD Medication 48 SCD HeFT 48 Improving Patient Safety 48 Epidemiological Studies Unit 48 Schizophrenia Drug 48 Cell Transplant 48 Provides Detailed 48 ConclusionThis 48 Hepatitis C Treatment 48 Certej Project 48 Analytiqa 48 Safe Medication 48 Inhaled Liposomal Ciprofloxacin 48 Treatment Naive Patients 48 Prescriber 48 Chronic Lyme Disease 48 Successful Implementation 48 Geochemical Survey 48 NEVO RES 48 Hospitalized Patients 48 Targeted Therapeutics 48 JAK2 Inhibitor 48 Injectable Drug 48 Cites Positive 48 SPIVA 48 Antiangiogenic 48 Overactive Bladder 48 Musculo Skeletal Disorders 48 Natural Catastrophe Stress 48 Spatio Temporal 48 Antipsychotic Drug 48 Maximum Tolerated Dose MTD 47 Pharmacologic 47 Therapeutic Monoclonal Antibodies 47 Effectiveness 47 Misys Healthcare Experience 47 demonstrated clinically meaningful 47 Heart Failure Therapy 47 BiTE Antibody 47 CATIE AD 47 Metabolic Disorder 47 SYMMETRY trial 47 Epidemiologic 47 Cervical Screening 47 Presents Preclinical Data 47 Aneurysm Repair 47 Reduced Risk 47 clinico pathological 47 Microbiological 47 Drug Resistant Tuberculosis 47 Bone Mineral Density 47 Prognostic Factors 47 Sarbanes Oxley Compliance 47 Virologic 47 Clinical Trial 47 Antidepressant Treatment 47 Related Mortality 47 NeuroImage 47 Recurrent Breast Cancer 47 Prostate Cancer Risk 47 Osteoporotic Fractures 47 HEOR 47 Bare Metal Stent 47 Potent Antiviral Activity 47 Viral Suppression 47 Deutsches Arzteblatt International 47 Septic Shock 47 Acta Paediatrica 47 Post hoc 47 Functional Outcomes 47 Prehospital Emergency Care 47 Chronic Heart Failure 47 Improve Survival 47 Broadband Subscriber 47 Strategic Insights 47 Showed Significant 47 Positive Scoping Study 47 Gender Disparity 47 Nanotoxicology 47 Antitumor 47 Patients Treated With 47 Vulnerable Plaque 47 Regulatory Frameworks 47 Adjuvant Chemotherapy 47 Protein Biomarker 47 Survival Benefit 47 pharmacoeconomic 47 Colorectal Cancer Screening 47 Vapor Intrusion 47 Achieve Maximum 47 Feasibility Analysis 47 Upward Revision 47 journal Gynecologic Oncology 47 selenium supplementation 47 neurotherapeutics 47 Investigational Agent 47 Seasonal Influenza Vaccine 47 Racial Disparities 47 PREVENT IV 47 Phase Ib clinical 47 Adaptive Clinical Trials 47 Biodegradable Polymers 47 Oral Insulin Capsule 47 Attack Trial ALLHAT 47 Results Confirm 47 Heart Failure Therapies 47 Performance Metrics 47 #F FDG PET CT 47 Urinary Incontinence 47 Small Molecule Drug 47 Bipolar Depression 47 Screening Trial DMIST 47 Cost Estimating 47 NO# [002] 47 Trodusquemine MSI 47 Solar Photovoltaic Market 47 Rapidly Evolving 47 Renal Tumors 47 Leadership Institute ASLI 47 Predictive Value 47 User Requirements 47 Clinical Psychopharmacology 47 Hyperlipidemia 47 phase Ib 47 Therapeutic Intervention 47 Marketrack 47 ongoing Phase 1b 47 Researchs 47 Evolving Role 47 Embolic Protection 47 Clinical Decision 47 Patients Receiving 47 Osteoporosis Treatment 47 Disease Modification 47 Statistical Analysis 47 Smooth Muscle 47 Vascular Disease 47 Inhaled Nitric Oxide 47 Experimental Pharmacology 47 CARDIA 47 ACCEDE 47 Postdoctoral Position 47 Controlled Study 47 Phase 2b kidney transplant 47 AACR San Antonio 47 Geochimica et Cosmochimica Acta 47 ADAGIO 47 Industry Concentration 47 Structured Content 47 Treatment Outcomes 47 Evidenced Based 47 SUTENT ® 47 Reevaluation 47 Strategy 47 Total Knee Arthroplasty 47 Psychological Assessment 47 Revascularization 47 Investigational Treatment 47 Solid Tumor 47 Diabetic Kidney Disease 47 Physician Retention 47 Oncotype DX ® 47 CT Angiography 47 Analysis RCPL Forex 47 Drug Metabolism 47 Dual Antiplatelet Therapy 47 Long Term Outcomes 47 INDEPTH 47 Ventricular Arrhythmias 47 Stakeholder Workshop 47 Retinal Vein Occlusion 47 Cleaner Coal 47 Genetic Variation 47 Valvular Heart Disease 47 Product Characteristics SmPC 47 Zacks PEG Ratio 47 registrational Phase 47 Multicentre 47 Vitro Activity 47 AIR2 Trial 47 Adjuvant 47 Circulation Heart Failure 47 Socioeconomic Status 47 Brownfield Renewal 47 Initiate Clinical Trial 47 Toxicological 47 retrospective cohort study 47 Hormonal Therapy 47 MAQC 47 Circulation Cardiovascular Quality 47 Improves Survival 47 Protein Structures 47 CombAT study 47 Statistical Methods 47 Mantel Haenszel 47 Appropriateness Criteria 47 Biomarker 47 Osteoarthritis Patients 47 J Clin Oncol 47 Immunohistochemistry 47 methodologic 47 Feasibility 47 STRATEGY FOR AN OPEN 47 exploratory endpoints 47 Aortic Dissection 47 Unequal Treatment 47 Multi Disciplinary 47 Randomised Badger Culling 47 PROTECT II 47 Glycemic Control 47 Electrophysiology Mapping 47 #-# Full Text 47 Cognitive Abilities 47 Patients Undergoing 47 Anemia Drug 47 Organizational Realignment 47 Improve Outcomes 47 Veterinary Vaccines 47 Lord Darzi NHS 47 Analytical Biochemistry 47 Neuroendocrine Tumors 47 Sleep Disturbance 47 Systemic Sclerosis 47 Testing Methodology 47 Intravenous Equipment 47 respected Urchin 47 Solid Tumours 47 Lifestyle Intervention 47 Clinical Validation 47 Outcomes Research 47 Cognitive Function 47 CINQUIL 47 Lower Extremity 47 Iron Deficiency 47 ACS NSQIP 47 Epilepsy Drug 47 fluorodeoxyglucose positron emission tomography 47 IMS MIDAS 47 AIDS Clinical Trials 46 Indepth 46 Proven Effective 46 Preliminary Assessment Study 46 Thyroid Hormone 46 Prostate Cancer Detection 46 Uterine Fibroid 46 Neuroepidemiology 46 Improving Patient 46 Protein Interaction 46 Coronary Angiography 46 Relieve Depression 46 Valve Replacement 46 Pharmacological 46 Peripheral Arterial 46 Statin Therapy 46 Systolic Blood Pressure 46 Acta Scandinavica 46 journal Ambulatory Pediatrics 46 Myelodysplastic Syndromes 46 Parenteral Nutrition 46 journal Epilepsia 46 ICAAC IDSA 46 Chemoprevention 46 Dose Response 46 Childhood Asthma 46 Resource Allocation 46 Outcomes Assessment 46 Malaria Vaccine 46 Stakeholder Engagement